Certain types of life science research involving “high consequence pathogens and toxins” would be subject to new review and risk mitigation procedures which might include classification of the research or termination of the funding, according to a U.S. government policy issued yesterday by the National Institutes of Health.
The policy applies to research involving 15 specified biological agents and toxins which “pose the greatest risks of deliberate misuse with most significant potential for mass casualties or devastating effects to the economy, critical infrastructure or public confidence.”
Research that increases the lethality or transmissibility of the agent or toxin, or otherwise enhances its harmful consequences, will be subject to the new review procedures.
Based on the outcome of the review, a risk mitigation plan may be developed. If less restrictive measures were deemed inadequate, the new policy would allow for national security classification of the research or termination of government funding.
See “United States Government Policy for Oversight of Life Sciences Dual Use Research of Concern,” March 29, 2012.
See also “U.S. Requires New Dual-Use Biological Research Reviews” by David Malakoff, Science Insider, March 29.
While the U.S. has made significant advancements and remained a global leader in biotechnology over the past decade, the next four years will be critical in determining whether it can sustain that leadership.
As the efficacy of environmental laws has waned, so has their durability. What was once a broadly shared goal – protecting Americans from environmental harm – is now a political football, with rules that whipsaw back and forth depending on who’s in charge.
It takes the average person over 9 hours and costs $160 to file taxes each year. IRS Direct File meant it didn’t have to.
It’s paramount to balance both innovation capabilities and risk as we work towards ensuring that the U.S. bioeconomy is a priority area for both the Nation and for National Security.